Device sales, including AirSense 10 and AirSense 11 ... and potentially redefining market standards for CPAP masks. ResMed also collaborated with Apple Vision Pro to introduce the Kontor Head ...

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Hello, everyone, and welcome to ResMed's second-quarter ... reflecting the continuing demand for our AirSense 10 and AirSense 11 platforms. Device sales remained strong, growing double digits year ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

ResMed Inc.’s RMD adjusted earnings per share ... Global device sales were driven by strong market performance from both the AirSense 10 and the AirSense 11 platforms. A strong focus on ...